"There is no greater threat to the integrity of the clinical research enterprise than the appearance or reality of a conflict of interest-be it financial, academic, or scientific." 1 This is from the American Society for Clinical Oncology (ASCO) guideline on oversight of clinical research, and it would seem to apply also for the NCCN guidelines, which are created by experts from leading academic oncology centers and built on results of research and clinical judgment.
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